NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.24 +0.07 (+1.35 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$5.17
Today's Range$4.65 - $6.00
52-Week Range$3.31 - $10.54
Volume13.85 million shs
Average Volume890,173 shs
Market Capitalization$209.51 million
P/E Ratio-6.55
Dividend YieldN/A
Beta3.19
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid. The multiple dose forms are intense to maximize the therapeutic range of ganaxolone for adults and pediatric patients. Ganaxolone acts as an anti-seizure, anti-anxiety, and anti-depressive actions; and acts on synaptic and extra synaptic GABAA receptors. The company is also developing ganaxolone for pediatric refractory epilepsy; postpartum depression; and acute epilepsy, which are in Phase II clinical study. In addition, it is developing ganaxolone IV formulation to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
Previous Symbol
CUSIPN/A
Phone484-801-4670

Debt

Debt-to-Equity RatioN/A
Current Ratio5.94
Quick Ratio5.94

Price-To-Earnings

Trailing P/E Ratio-6.55
Forward P/E Ratio-5.63
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.43 per share
Price / Book3.66

Profitability

EPS (Most Recent Fiscal Year)($0.80)
Net Income$-18,890,000.00
Net MarginsN/A
Return on Equity-65.57%
Return on Assets-60.74%

Miscellaneous

Employees16
Outstanding Shares40,530,000
Market Cap$209.51 million
OptionableOptionable

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) released its earnings results on Monday, October, 29th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.06. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

6 analysts have issued 1-year target prices for Marinus Pharmaceuticals' shares. Their forecasts range from $13.00 to $33.00. On average, they anticipate Marinus Pharmaceuticals' share price to reach $21.8571 in the next year. This suggests a possible upside of 317.1% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (11/2/2018)
  • 2. Mizuho analysts commented, "We highlighted our expectations for the phase 2 data in a previous note (available here). Magnolia is a multiple dose escalation study with ~60 patients randomized 1:1 with multiple dose cohorts and therefore not designed to hit statistical significance, in contrast to the phase 2 trial of Sage Therapeutics (SAGE, not rated) which was designed with a specific dose of brexanolone. In our view, the most important information to look for in the results will be a signal of efficacy along with information on a specific dose to be taken into Magnolia study." (9/25/2018)
  • 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD, and undervaluation relative to peers, we believe Marinus shares offer a compelling risk- reward profile. The company has three important data read-outs remaining in 4Q18, which we believe could become significant catalysts for the shares. Valuation Summary We arrive at our 12-month PT of $19/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (9/17/2018)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

Press coverage about MRNS stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 1.9 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the company's share price in the next few days.

Who are some of Marinus Pharmaceuticals' key competitors?

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Christopher Michael Cashman, Exec. Chairman, CEO & Pres (Age 61)
  • Mr. Edward F. Smith, CFO, VP, Treasurer & Sec. (Age 47)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 57)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations
  • Dr. Kimberly A. McCormick, Head of Regulatory Affairs

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.18%), Jennison Associates LLC (4.69%), Franklin Resources Inc. (4.40%), Partner Fund Management L.P. (4.38%), Vanguard Group Inc. (3.85%) and Credit Suisse AG (2.55%). Company insiders that own Marinus Pharmaceuticals stock include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which major investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Franklin Resources Inc., TIAA CREF Investment Management LLC, Virtus ETF Advisers LLC and Vanguard Group Inc.. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which major investors are buying Marinus Pharmaceuticals stock?

MRNS stock was acquired by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., Credit Suisse AG, VHCP Management III LLC, Tekla Capital Management LLC, BlackRock Inc., Fosun International Ltd, Point72 Asset Management L.P. and Jane Street Group LLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $5.24.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $209.51 million. The biopharmaceutical company earns $-18,890,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Marinus Pharmaceuticals employs 16 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 170 N. Radnor Chester Rd Suite 250, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  239 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel